| Migraine |
1 |
1 |
| Headache |
0 |
0.57 |
| Disability |
0 |
0.29 |
| Insurance |
0 |
0.29 |
| Nonopioid Pain Management |
0 |
0.25 |
| Pain Management |
0 |
0.25 |
| Adverse Effects |
0 |
0.23 |
| Revenue and Practice Management |
0 |
0.8 |
| Clinical Guidelines |
0 |
0.75 |
| Clinical Research |
0 |
0.17 |
| Health Care Quality, Access, and Evaluation |
0 |
0.6 |
| Pain |
0 |
0.17 |
| Receptors |
0 |
0.17 |
| Patient Safety |
0 |
0.15 |
| Cyclic Antidepressants |
0 |
0.13 |
| Analgesia |
0 |
0.12 |
| Aura |
0 |
0.12 |
| Beta Blockers |
0 |
0.12 |
| Coronary Artery Disease (CAD) |
0 |
0.12 |
| Depression |
0 |
0.12 |
| Medication Overuse Headache (MOH) |
0 |
0.12 |
| Nonpharmacologic |
0 |
0.12 |
| Nonsteroidal Anti-Inflammatory Agents (NSAIDs) |
0 |
0.12 |
| Social Determinants of Health |
0 |
0.1 |
| Adherence |
0 |
0.06 |
| Antidepressant drug |
0 |
0.06 |
| Anxiety |
0 |
0.06 |
| Artery |
0 |
0.06 |
| Aspirin |
0 |
0.06 |
| California |
0 |
0.06 |
| Cardiovascular disease |
0 |
0.06 |
| Cardiovascular Risk Management |
0 |
0.06 |
| Emesis |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Hand |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Hypertension |
0 |
0.06 |
| Id Reaction |
0 |
0.06 |
| Impairment |
0 |
0.06 |
| Intravenous |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Nausea |
0 |
0.06 |
| SNRI |
0 |
0.06 |
| Washington |
0 |
0.06 |
| Anxiety Disorder |
0 |
0.03 |
| Biologic Therapy |
0 |
0.03 |
| Dermatitis |
0 |
0.03 |